<DOC>
	<DOCNO>NCT03085225</DOCNO>
	<brief_summary>A phase Ib trial study trabectedin prescribe combination durvalumab locally advanced/unresectable soft-tissue sarcoma ovarian carcinoma .</brief_summary>
	<brief_title>Trabectedin Combined With Durvalumab Patients With Advanced Pretreated Soft-tissue Sarcomas Ovarian Carcinomas .</brief_title>
	<detailed_description>This multicenter , prospective phase Ib trial base dose escalation study design ( 3+3 traditional design ) assess three dose level Trabectedin give durvalumab , follow two expansion cohort MTD establish .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>1 . Histology : Softtissue sarcoma histologically confirm . In care outside center RRePS Network , central review necessary ( Pr . Coindre team ) , histologically confirm ovarian carcinoma ( carcinosarcoma include ) , 2. ovarian carcinoma without know g/s BRCA mutation : platinum sensitive ovarian carcinoma relapse ( &gt; 12 month ) non suitable platinum rechallenging treatment , intermediate platinum sensitive ovarian carcinoma relapse ( 612 month ) . 3 . Metastatic unresectable locally advanced disease , 4 . Age ≥ 18 year , 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤ 1 , 6 . Life expectancy &gt; 3 month , 7 . Patients must measurable disease ( lesion previously irradiate file consider measurable progressive inclusion accord RECIST 1.1 ) define per RECIST v1.1 least one lesion measure least one dimension ( long diameter record ) &gt; 10 mm spiral CT scan . 8 . Documented disease progression accord RECIST v1.1 study entry , 9 . Patient must comply collection tumor biopsy , 10 . At least 1 line chemotherapy palliative setting use Anthracyclines ( STS ) , platinum contain regimen ( ovarian carcinoma ) , 11 . At least three week since last chemotherapy , immunotherapy pharmacological treatment and/or radiotherapy , 12 . Adequate hematological , renal , metabolic hepatic function : 1 . Hemoglobin ≥ 9 g/dl ( patient may receive prior red blood cell [ RBC ] transfusion , clinically indicate ) ; absolute neutrophil count ( ANC ) ≥ 1.5 x 109/l , platelet count ≥ 100 x 109/l . 2 . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≤ 2.5 x upper limit normality ( ULN ) ( ≤ 5 case extensive liver involvement ) alkaline phosphatase ( AP ) ≤ 2.5 x ULN . 3 . Total bilirubin ≤ ULN . 4 . Albumin ≥ 25 g/l . 5 . Calculated creatinine clearance ( CrCl ) &gt; 40 ml/min ( accord Cockroft Gault formula ) . 6 . Thyroid function within normal laboratory range ( TSH , free T3 , free T4 ) . 13 . Women childbearing potential must negative serum pregnancy test within 72 hour prior receive first dose trial medication . Both woman men must agree use highly effective method contraception throughout treatment period six month discontinuation treatment . Acceptable method contraception describe protocol section 7.6.1.1 , 14 . No prior concurrent malignant disease diagnose treat last 2 year except adequately treat situ carcinoma cervix , basal squamous skin cell carcinoma , situ transitional bladder cell carcinoma , 15 . Recovery grade ≤ 1 adverse event ( AE ) derive previous treatment ( exclude alopecia grade nonpainful peripheral neuropathy grade ≤ 2 ) accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE , version 4.0 ) , 16 . Voluntarily sign date write informed consent prior study specific procedure , 17 . Patients social security compliance French law relate biomedical research ( Article 112111 French Public Health Code ) . 1 . Previous treatment Trabectedin antiPD1 , antiPDL1 , antiPDL2 , include durvalumab 2 . Current prior use immunosuppressive medication medication include use oral glucocorticoid , within 21 day first dose durvalumab , exception intranasal inhaled corticosteroid systemic corticosteroid physiological dos 3 . Active prior document inflammatory bowel disease ( e.g. , Crohn 's disease , ulcerative colitis ) , 4 . Has active autoimmune disease require systemic treatment within past 2 year ( ie , use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( e.g. , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insuddiciency ) consider form systemic treatment , 5 . Has evidence active noninfectious pneumonitis , 6 . Has active infection require systemic therapy , 7 . Currently active bacterial fungus infection ( &gt; grade 2 CTC [ CTCAE ] HIV1 , HIV2 , hepatitis A hepatitis B hepatitis C infection , 8 . Known central nervous system malignancy ( CNS ) , 9 . Men woman childbearing potential use effective method contraception previously describe ; woman pregnant breast feeding , 10 . Previous enrolment present study , 11 . Patient unable follow comply study procedure geographical , social psychological reason , 12 . Has receive live vaccine within 30 day prior first dose trial treatment . Note : kill virus vaccine use seasonal influenza vaccine injection allow ; however intranasal influenza vaccine ( e.g. , FluMist® ) live attenuate vaccine allow . 13 . Known hypersensitivity involve study drug formulation component , 14 . Tumors accessible biopsy , 15 . Known history active tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Advanced tumor</keyword>
	<keyword>Pretreated tumor</keyword>
	<keyword>Soft Tissue Sarcomas</keyword>
	<keyword>Ovarian Carcinomas</keyword>
	<keyword>Phase Ib</keyword>
	<keyword>Circulating DNA</keyword>
</DOC>